Three Movers to Watch for: Mast Therapeutics, Inc. (MSTX), Bristol-Myers Squibb Company (BMY), Chevron Corporation (CVX)

Mast Therapeutics, Inc. (MSTX) grew with the stock adding 7.37% or $0 to close at $0.1 on light trading volume of 6.72M compared its three months average trading volume of 7.39M. The San Diego California 92130 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -76.28% down for the period and up by 17.51% so far this year. With price target of $2.75 and a 45.71% rebound from 52-week low, Mast Therapeutics, Inc. has plenty of upside potential, making it a hold with a view buy.

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. The company’s lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Bristol-Myers Squibb Company (BMY) dropped $-0.31 to close the day at a new closing price of $59.14, a -0.52% decrease in value from its previous closing price that moved the stock 20.62% above its 52 week low of $49.03. A total of 6.7M shares exchanged hands during the day compared with its three month average trading volume of 11.63M. The stock, which fluctuated between $59.03 and $59.75 during the day, currently situated -22.78% below its 52 week high. The stock is up by 5.68% in the past one month and up by 7.86% over the past three months. With a one year target estimate of $62.53 and RSI of 63.81, the stock still has upside potential, making it a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Chevron Corporation (CVX) shares were down in last trading by -0.03% to $117.82. It experienced lighter than average volume on day. The stock decreased in value by almost -0.34% over the past week and grew 4.27% in the past month. It is currently trading 6.51% above its 50 day moving average and 15.55% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -0.99% decrease in value from its one year high of $119. The RSI indicator value of 68.66, lead us to believe that it is a hold for now.

Chevron Corporation, through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, and production of crude oil and natural gas; processing, liquefaction, transportation, and regasification associated with liquefied natural gas; transportation of crude oil through pipelines; and transportation, storage, and marketing of natural gas, as well as operates a gas-to-liquids plant. The Downstream segment engages in refining crude oil into petroleum products; marketing crude oil and refined products; transporting crude oil and refined products through pipeline, marine vessel, motor equipment, and rail car; and manufacturing and marketing commodity petrochemicals, and fuel and lubricant additives, as well as plastics for industrial uses. It is also involved in the cash management and debt financing activities; corporate administrative operations; insurance operations; real estate activities; and technology businesses. Further, the company holds interests in power plants, as well as operates geothermal plants; and engages in the transportation of refined products primarily in the coastal waters of the United States. The company was formerly known as ChevronTexaco Corporation and changed its name to Chevron Corporation in 2005. Chevron Corporation was founded in 1879 and is headquartered in San Ramon, California.

 

Stocks Intraday Alert: Hecla Mining Company (HL), Staples, Inc. (SPLS), Bristol-Myers Squibb Company (BMY)

Hecla Mining Company (HL) managed to rebound with the stock climbing 4.96% or $0.26 to close the day at $5.5 on higher than average trading volume of 9.97M shares, compared to its three month average trading volume of 12.33M. The Coeur d'Alene Idaho 83815 based company has been outperforming the silver companies by -2.7309% for last three months and its recent losses have trimmed gains to 4.96% YTD, versus the silver industry which is down -19.31% for the same period. The RSI of 46.21 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Hecla Mining Company, together with its subsidiaries, discovers, acquires, develops, produces, and markets precious and base metal deposits worldwide. The company offers unrefined gold and silver bullion bars to precious metals traders; and lead, zinc, and bulk concentrates to custom smelters and brokers. It owns 100% interests in the Greens Creek mine located on Admiralty Island in Southeast Alaska; the Lucky Friday unit located in the Coeur d’Alene mining district in northern Idaho; the Casa Berardi mine located in the Abitibi region of north-western Quebec, Canada; and the San Sebastian unit located in the state of Durango, Mexico. The company was founded in 1891 and is based in Coeur d’Alene, Idaho.

Staples, Inc. (SPLS) had a active trading with around 9.88M shares changing hands compared to its three month average trading volume of 8.6M. The stock traded between $8.82 and $9.18 before closing at the price of $8.89 with -1.77% change on the day. The Framingham Massachusetts 01701 based company is currently trading 24.29% above its 52 week low of $7.24 and -18.62% below its 52 week high of $11.37. Both the RSI indicator and target price of 40.53 and $9.92 respectively, lead us to believe that it should be put on hold over the coming weeks.

Staples, Inc., together with its subsidiaries, operates office products superstores. It operates in three segments: North American Stores & Online, North American Commercial, and International Operations. The company offers a range of office supplies, business technology products, facility and breakroom supplies, computers and mobility products, and office furniture under the Staples, Quill, and other proprietary brands. It also provides copy and print services, as well as technology services. The company sells and delivers office products and services directly to businesses and consumers through its Staples.com and Staples.ca, and Quill.com Websites, as well as through retail stores, and Internet and direct mail catalogs. As of January 30, 2016, it operated approximately 1,907 retail stores; and 104 distribution and fulfillment centers in the United States and internationally. The company was founded in 1985 and is based in Framingham, Massachusetts.

Bristol-Myers Squibb Company (BMY) traded within a range of $58.58 to $59.68 after opening the day at $58.78. The company has seen its stock increase in value by 1.73% so far this year. The stock was up close to 1.73% on light volume in last trading session and closed at $59.45 per share. After the recent gain, the stock is currently holding -22.38% below its 52 week high of $77.12 and 21.25% above its 12-month low of $49.03. The shares are up by over 9.52% in the last three months, and the RSI indicator value of 65.94 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Alert: Bristol-Myers Squibb Company (BMY), The Walt Disney Company (DIS), CenturyLink, Inc. (CTL)

Bristol-Myers Squibb Company (BMY) retreated with the stock falling -0.78% or $-0.46 to close at $58.44 on active trading volume of 7.01M compared its three months average trading volume of 11.73M. The New York New York 10154 based company operating under the Drug Manufacturers – Major industry has been trending down for the last 52 weeks, with the shares price now -13.49% down for the period and down by -13.49% so far this year. With price target of $62.53 and a 19.19% rebound from 52-week low, Bristol-Myers Squibb Company has plenty of upside potential, making it a hold with a view buy.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

The Walt Disney Company (DIS) dropped $-0.34 to close the day at a new closing price of $104.22, a -0.33% decrease in value from its previous closing price that moved the stock 22.65% above its 52 week low of $86.25. A total of 6.64M shares exchanged hands during the day compared with its three month average trading volume of 8.06M. The stock, which fluctuated between $103.96 and $105 during the day, currently situated -1.92% below its 52 week high. The stock is up by 5.96% in the past one month and up by 13.1% over the past three months. With a one year target estimate of $107.85 and RSI of 65.32, the stock still has upside potential, making it a hold for now.

The Walt Disney Company, together with its subsidiaries, operates as an entertainment company worldwide. The company’s Media Networks segment operates cable programming services, including the ESPN, Disney channels, and Freeform networks; broadcast businesses, which include the ABC TV Network and eight owned television stations; radio businesses consisting of the ESPN Radio Network; and the Radio Disney network. It also produces and sells original live-action and animated television programming to first-run syndication and other television markets, as well as subscription video on demand services and in home entertainment formats, such as DVD, Blu-Ray, and iTunes. Its Parks and Resorts segment owns and operates the Walt Disney World Resort in Florida and the Disneyland Resort in California. This segment also operates Disney Resort & Spa in Hawaii, Disney Vacation Club, Disney Cruise Line, and Adventures by Disney; and manages Disneyland Paris, Hong Kong Disneyland Resort, and Shanghai Disney Resort, as well as licenses its intellectual property to a third party for the operations of the Tokyo Disney Resort in Japan. The company’s Studio Entertainment segment produces and acquires live-action and animated motion pictures for distribution in the theatrical, home entertainment, and television markets primarily under the Walt Disney Pictures, Pixar, Marvel, Lucasfilm, and Touchstone banners. This segment also produces stage plays and musical recordings; licenses and produces live entertainment events; and provides visual and audio effects, and other post-production services. Its Consumer Products & Interactive Media segment licenses its trade names, characters, and visual and literary properties; develops and publishes games for mobile platforms; and sells its products through The Disney Store, DisneyStore.com, and MarvelStore.com, as well as directly to retailers. The company was founded in 1923 and is based in Burbank, California.

CenturyLink, Inc. (CTL) shares were down in last trading by -1.04% to $23.78. It experienced lighter than average volume on day. The stock decreased in value by almost -0.38% over the past week and grew 1.11% in the past month. It is currently trading -3.64% below its 50 day moving average and -12.33% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -27.35% decrease in value from its one year high of $33.45. The RSI indicator value of 44.42, lead us to believe that it is a hold for now.

CenturyLink, Inc. provides various communications services to residential, business, wholesale, and governmental customers in the United States. It operates through two segments, Business and Consumer. The company offers high-speed Internet services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; multi-protocol label switching, a data networking technology to support real-time voice and video; and private line services for the transmission of data between sites. It also provides Ethernet services, including point-to-point and multi-point equipment configurations that facilitate data transmissions across metropolitan areas and wide area networks (WAN); colocation services that enable its customers to install their own information technology (IT) equipment; and managed hosting services comprising cloud and traditional computing, application management, back-up, storage, and other services. In addition, the company offers video entertainment services and satellite digital television; Voice over Internet Protocol, a real-time, two-way voice communication service; and managed services that consist of network, hosting, cloud, and IT services. Further, it provides local calling, long-distance voice, integrated services digital network, WAN, and switched access services; and data integration, which includes the sale of telecommunications equipment and providing network management, installation, and maintenance of data equipment, and the building of proprietary fiber-optic broadband networks. Additionally, the company leases and subleases space in its office buildings, warehouses, and other properties. As of December 31, 2015, it served approximately 6 million high-speed Internet subscribers and 285 thousand television subscribers; and operated 59 data centers in North America, Europe, and Asia. CenturyLink, Inc. was founded in 1968 and is headquartered in Monroe, Louisiana.

 

3 Notable Runners: Transgenomic, Inc. (TBIO), Bristol-Myers Squibb Company (BMY), ConocoPhillips (COP)

Transgenomic, Inc. (TBIO) managed to rebound with the stock climbing 20.83% or $0.05 to close the day at $0.29 on lower than average trading volume of 3.66M shares, compared to its three month average trading volume of 596.52K. The Omaha Nebraska 68164 based company has been outperforming the scientific & technical instruments companies by -0.088% for last three months and its recent losses have trimmed gains to -72.9% YTD, versus the scientific & technical instruments industry which is up 18.27% for the same period. The RSI of 54.76 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies, and clinical and research services primarily in the United States. The company provides genetic analytical laboratory services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. It employs various genomic testing service technologies, including ICE COLD-PCR, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The company was founded in 1997 and is headquartered in Omaha, Nebraska.

Bristol-Myers Squibb Company (BMY) had a active trading with around 3.64M shares changing hands compared to its three month average trading volume of 11.95M. The stock traded between $58.63 and $59.19 before closing at the price of $58.9 with 0.49% change on the day. The New York New York 10154 based company is currently trading 20.13% above its 52 week low of $49.03 and -23.1% below its 52 week high of $77.12. Both the RSI indicator and target price of 63.93 and $62.53 respectively, lead us to believe that it should be put on hold over the coming weeks.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

ConocoPhillips (COP) traded within a range of $50.24 to $50.82 after opening the day at $50.66. The company has seen its stock increase in value by 11.01% so far this year. The stock was down close to -0.45% on light volume in last trading session and closed at $50.54 per share. After the recent fall, the stock is currently holding -4.95% below its 52 week high of $53.17 and 65.64% above its 12-month low of $31.05. The shares are up by over 16.43% in the last three months, and the RSI indicator value of 56.86 is neither bullish nor bearish, tempting investors to stay on the sidelines.

ConocoPhillips explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids worldwide. Its portfolio includes resource-rich North American tight oil and oil sands assets; lower-risk legacy assets in North America, Europe, Asia, and Australia; various international developments; and an inventory of conventional and unconventional exploration prospects. The company was founded in 1917 and is headquartered in Houston, Texas.

 

Stocks in Focus: Bristol-Myers Squibb Company (BMY), Gilead Sciences Inc. (GILD), The Procter & Gamble Company (PG)

Bristol-Myers Squibb Company (BMY) had a active trading with around 5.41M shares changing hands compared to its three month average trading volume of 12.17M. The stock traded between $58.77 and $59.92 before closing at the price of $59.61 with 1.45% change on the day. The New York New York 10154 based company is currently trading 21.58% above its 52 week low of $49.03 and -22.17% below its 52 week high of $77.12. Both the RSI indicator and target price of 71.75 and $62.53 respectively, lead us to believe that it could drop over the coming weeks.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Gilead Sciences Inc. (GILD) managed to rebound with the stock climbing 0.46% or $0.34 to close the day at $73.64 on light trading volume of 5.31M shares, compared to its three month average trading volume of 9.64M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -27.26%, compared to the industry which has dropped -7.56% over the same period. With RSI of 48.44, the stock should still continue to rise and get closer to its one year target estimate of $95.19, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

The Procter & Gamble Company (PG) shares were up in last trading by 0.58% to $84.96. It experienced lighter than average volume on day. The stock increased in value by almost 0.33% over the past week and grew 2.76% in the past month. It is currently trading 0.34% above its 50 day moving average and 1.5% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -5.22% decrease in value from its one year high of $90.33. The RSI indicator value of 54.14, lead us to believe that it is a hold for now.

The Procter & Gamble Company provides branded consumer packaged goods to consumers in North America, Europe, the Asia Pacific, India, the Middle East, Africa, and Latin America. The company’s Beauty segment offers hair care products comprising conditioners, shampoos, styling aids, and treatments; and antiperspirants and deodorants, personal cleansing, and skin care products. This segment markets its products under the Head & Shoulders, Olay, Pantene, Rejoice, Old Spice, Safeguard, and SK-II brands. Its Grooming segment provides blades and razors, pre- and post-shave products, and other shave care products, as well as appliances under the Braun, Fusion, Gillette, Mach3, Prestobarba, and Venus brands. The company’s Health Care segment offers toothbrushes, toothpaste, and other oral care products; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, and other healthcare products under the Oral-B, Crest, Prilosec, Vicks, Metamucil, Pepto Bismol, and Align brands. Its Fabric & Home Care segment provides fabric care products, including fabric enhancers, laundry additives, and laundry detergents; and home care products comprising air care, dish care, P&G professional, and surface care products under the Tide, Ariel, Downy, Gain, Cascade, Dawn, Febreze, Mr. Clean, and Swiffer brands. The company’s Baby, Feminine & Family Care segment offers baby care products, such as baby wipes, diapers, and pants; adult incontinence and feminine care products; and family care products, such as paper towels, tissues, and toilet papers. This segment markets its products under the Pampers, Always, Bounty, Charmin, Luvs, and Tampax brands. The company sells its products through mass merchandisers, grocery stores, membership club stores, drug stores, department stores, distributors, baby stores, specialty beauty stores, e-commerce, high-frequency stores, and pharmacies. The Procter & Gamble Company was founded in 1837 and is based in Cincinnati, Ohio.

 

Stocks To Track: The Finish Line, Inc. (FINL), Eli Lilly and Company (LLY), Bristol-Myers Squibb Company (BMY)

The Finish Line, Inc. (FINL) fell -5.29% during last trading as the stock lost $-1.11 to finish the day at $19.89 with about 4.83M shares changing hands, compared to its three month average trading volume of 1.42M. The $817.88M market cap company, which fluctuated between $19.8 and $20.57 during the day, currently situated 28.89% above its 52 week low of $15.74 and -18.82% away from its one year high of $24.52. The RSI of 30.86 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

The Finish Line, Inc., together with its subsidiaries, operates as a specialty retailer of athletic shoes, apparel, and accessories in the United States. It operates in two divisions, the Finish Line and JackRabbit. The company’s Finish Line division engages in the in-store and online retail of athletic shoes for Macy’s Retail Holdings, Inc.; Macy’s Puerto Rico, Inc.; and Macys.com, Inc., as well as online at macys.com. This division offers men’s, women’s, and kids’ athletic shoes, as well as an assortment of accessories of Nike, Skechers, Converse, Puma, New Balance, Adidas, and other brands. As of April 2, 2016, the company operated Finish Line shops in 392 Macy’s department stores in 37 states in the United States, the District of Columbia, and Puerto Rico. Its JackRabbit division retails lifestyle products, such as running shoes, apparel, and accessories of Brooks, Asics, Nike, Saucony, New Balance, and other brands. It also operates the e-commerce sites jackrabbit.com and boulderrunningcompany.com. The company operated 72 JackRabbit stores in 17 states in the United States and the District of Columbia. The company also offers products through its e-commerce site, finishline.com and mobile commerce site, m.finishline.com. The company was founded in 1976 and is based in Indianapolis, Indiana.

Eli Lilly and Company (LLY) gained $0.01 to close the day at a new closing price of $73.26, a 0.01% increase in value from its previous closing price that moved the stock 14.15% above its 52 week low of $64.18. A total of 4.83M shares exchanged hands during the day compared with its three month average trading volume of 5.99M. The stock, which fluctuated between $72.68 and $73.48 during the day, currently situated -13.63% below its 52 week high. The stock is down by -3.59% in the past one month and down by -9.14% over the past three months. With a one year target estimate of $84.1 and RSI of 57.24, the stock still has upside potential, making it a hold for now.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Bristol-Myers Squibb Company (BMY) had a active trading with around 4.81M shares changing hands compared to its three month average trading volume of 12.26M. The stock traded between $58.51 and $58.98 before closing at the price of $58.76 with 0.12% change on the day. The New York New York 10154 based company is currently trading 19.84% above its 52 week low of $49.03 and -23.28% below its 52 week high of $77.12. Both the RSI indicator and target price of 67.51 and $62.11 respectively, lead us to believe that it should be put on hold over the coming weeks.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Trend Analysis: General Growth Properties, Inc (GGP) Bristol-Myers Squibb Company (BMY) Clovis Oncology, Inc. (CLVS)

General Growth Properties, Inc (GGP) continued its downward trend with the stock declining -2.68% or $-0.7 to close the day at $25.38 on active trading volume of 4.44M shares, compared to its three month average trading volume of 4.33M. The Chicago Illinois 60606 based company has been underperforming the reit – retail group over the past 52 weeks, with the stock losing -3.42%, compared to the industry which has advanced 1.01% over the same period. With RSI of 43.56, the stock should still continue to rise and get closer to its one year target estimate of $31.56, making it a hold for now.

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.

Bristol-Myers Squibb Company (BMY) retreated with the stock falling -0.73% or $-0.43 to close at $58.69 on active trading volume of 4.43M compared its three months average trading volume of 12.37M. The New York New York 10154 based company operating under the Drug Manufacturers – Major industry has been trending down for the last 52 weeks, with the shares price now -12.03% down for the period and down by -13.12% so far this year. With price target of $62.11 and a 19.7% rebound from 52-week low, Bristol-Myers Squibb Company has plenty of upside potential, making it a hold with a view buy.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Clovis Oncology, Inc. (CLVS) continued its upward trend with the stock climbing 8.65% or $3.68 to close the day at $46.2 on higher than average trading volume of 4.41M shares, compared to its three month average trading volume of 2.72M. The Boulder Colorado 80301 based company has been underperforming the biotechnology companies by 20.4508% for last three months and its recent gains have pushed the stock slightly up 32% YTD, versus the biotechnology industry which is up 0.71% for the same period. The RSI of 73.99 indicates the stock is overbought at the current levels, sell for now.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast cancers. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

 

Momentum Stocks in Focus: Bristol-Myers Squibb Company (BMY), Pier 1 Imports, Inc. (PIR), Reynolds American Inc. (RAI)

Bristol-Myers Squibb Company (BMY) failed to extend gains with the stock declining -0.5% or $-0.3 to close the day at $59.12 on active trading volume of 3.9M shares, compared to its three month average trading volume of 12.46M. The New York New York 10154 based company has been underperforming the drug manufacturers – major group over the past 52 weeks, with the stock losing -11.04%, compared to the industry which has advanced 1.68% over the same period. With RSI of 70.13, the stock should still continue to rise and get closer to its one year target estimate of $62.11, making it a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Pier 1 Imports, Inc. (PIR) grew with the stock adding 5.33% or $0.48 to close at $9.49 on active trading volume of 3.89M compared its three months average trading volume of 2.9M. The Fort Worth Texas 76102 based company operating under the Specialty Retail, Other industry has been trending up for the last 52 weeks, with the shares price now 96.63% up for the period and up by 97.4% so far this year. With price target of $5.98 and a 162.91% rebound from 52-week low, Pier 1 Imports, Inc. has plenty of upside potential, making it a hold with a view buy.

Pier 1 Imports, Inc. engages in the retail sale of decorative accessories, furniture, candles, housewares, gifts, and seasonal products. It offers decorative accents and textiles, such as rugs, wall decorations and mirrors, pillows, bedding, lamps, vases, dried and artificial flowers, baskets, ceramics, dinnerware, candles, fragrance, gifts, and seasonal items. The company also provides furniture and furniture cushions that are used in living, dining, office, kitchen and bedroom areas, sunrooms, and patios. Further, it supplies merchandise and licenses the Pier 1 Imports name. The company sells its products through retail stores and e-Commerce Website. As of February 27, 2016, the company operated 953 stores in the United States and 79 stores in Canada. Pier 1 Imports, Inc. was founded in 1970 and is headquartered in Fort Worth, Texas.

Reynolds American Inc. (RAI) continued its upward trend with the stock climbing 0.02% or $0.01 to close the day at $55.98 on lower than average trading volume of 3.87M shares, compared to its three month average trading volume of 7.86M. The Winston-Salem North Carolina 27101 based company has been underperforming the cigarettes companies by 16.5306% for last three months and its recent gains have pushed the stock slightly up 25.48% YTD, versus the cigarettes industry which is down -2.65% for the same period. The RSI of 65.05 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.

 

Stocks Intraday Alert: Visa Inc. (V), The Coca-Cola Company (KO), Bristol-Myers Squibb Company (BMY)

Visa Inc. (V) continued its downward trend with the stock declining -0.32% or $-0.25 to close the day at $78.1 on higher than average trading volume of 8.68M shares, compared to its three month average trading volume of 10.29M. The San Francisco California 94128 based company has been outperforming the credit services companies by -5.1681% for last three months and its recent losses have trimmed gains to 1.48% YTD, versus the credit services industry which is up 8.88% for the same period. The RSI of 44.01 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Visa Inc. operates as a payments technology company worldwide. The company facilitates commerce through the transfer of value and information among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a processing network that enables authorization, clearing, and settlement of payment transactions; and offers fraud protection for account holders and assured payment for merchants. The company also offers gateway services for merchants to accept, process, and reconcile payments; manage fraud; and safeguard payment security online, as well as processing services for participating issuers of visa debit, prepaid, and ATM payment products. In addition, it provides digital products, including Visa Checkout that offers consumers an expedited and secure payment experience for online transactions; and Visa Direct, a push payment product platform, which facilitates payer-initiated transactions that are sent directly to the Visa account of the recipient, as well as Visa token service that replaces the card account numbers from the transaction with a token. Further the company offers corporate (travel) and purchasing card products, as well as value-added services. It provides its services under the Visa, Visa Electron, Interlink, V PAY, and PLUS brands. The company was incorporated in 2007 and is headquartered in San Francisco, California.

The Coca-Cola Company (KO) had a active trading with around 8.63M shares changing hands compared to its three month average trading volume of 14.04M. The stock traded between $41.58 and $41.8 before closing at the price of $41.67 with -0.17% change on the day. The Atlanta Georgia 30313 based company is currently trading 5.58% above its 52 week low of $39.88 and -9.42% below its 52 week high of $47.13. Both the RSI indicator and target price of 54.95 and $46.04 respectively, lead us to believe that it should be put on hold over the coming weeks.

The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages include nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters. The company’s still beverages comprise nonalcoholic beverages without carbonation, including noncarbonated waters, flavored and enhanced waters, noncarbonated energy drinks, juices and juice drinks, ready-to-drink teas and coffees, and sports drinks. It also provides flavoring ingredients, sweeteners, beverage ingredients, and fountain syrups, as well as powders for purified water products. The Coca-Cola Company sells its products primarily under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero, Fanta, Sprite, Minute Maid, Georgia, Powerade, Del Valle, Schweppes, Aquarius, Minute Maid Pulpy, Dasani, Simply, Glacéau Vitaminwater, Bonaqua/Bonaqa, Gold Peak, FUZE TEA, Glacéau Smartwater, and Ice Dew brand names. The company offers its beverage products through a network of company-owned or controlled bottling and distribution operators, as well as through independent bottling partners, distributors, wholesalers, and retailers. The Coca-Cola Company was founded in 1886 and is headquartered in Atlanta, Georgia.

Bristol-Myers Squibb Company (BMY) traded within a range of $59.02 to $59.85 after opening the day at $59.04. The company has seen its stock decrease in value by -12.04% so far this year. The stock was up close to 1.36% on light volume in last trading session and closed at $59.42 per share. After the recent gain, the stock is currently holding -22.42% below its 52 week high of $77.12 and 21.19% above its 12-month low of $49.03. The shares are up by over 7.69% in the last three months, and the RSI indicator value of 72.57 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Stocks Highlights: Sprint Corporation (S), Bristol-Myers Squibb Company (BMY), Cabot Oil & Gas Corporation (COG)

Sprint Corporation (S) had a light trading with around 12.13M shares changing hands compared to its three month average trading volume of 20.64M. The stock traded between $8.22 and $8.5 before closing at the price of $8.24 with -2.49% change on the day. The Overland Park Kansas 66251 based company is currently trading 277.98% above its 52 week low of $2.18 and -8.24% below its 52 week high of $8.98. Both the RSI indicator and target price of 56.69 and $7.28 respectively, lead us to believe that it should be put on hold over the coming weeks.

Sprint Corporation, through its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company operates in two segments, Wireless and Wireline. The Wireless segment offers wireless data communication services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; and mobile entertainment applications. It also provides wireless voice communications services that include local and long-distance wireless voice services, as well as voicemail, call waiting, three-way calling, caller identification, directory assistance, and call forwarding services. In addition, this segment offers voice and data services internationally through roaming arrangements; and customized wireless services to large companies and government agencies, as well as sells wireless devices, broadband devices, connected devices, and accessories to agents and other third-party distributors. The Wireline segment provides wireline voice and data communications, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol (IP), managed network services, Voice over IP, session initiated protocol, and traditional voice services to other communications companies, and targeted business and consumer subscribers, as well as for cable multiple system operators. Sprint Corporation offers its services under the Sprint, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. The company was founded in 1899 and is headquartered in Overland Park, Kansas. Sprint Corporation is a subsidiary of SoftBank Group Corp.

Bristol-Myers Squibb Company (BMY) failed to extend gains with the stock declining -0.05% or $-0.03 to close the day at $58.62 on light trading volume of 12.06M shares, compared to its three month average trading volume of 12.51M. The New York New York 10154 based company has been underperforming the drug manufacturers – major group over the past 52 weeks, with the stock losing -13.37%, compared to the industry which has advanced 1.3% over the same period. With RSI of 69.69, the stock should still continue to rise and get closer to its one year target estimate of $62.11, making it a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Cabot Oil & Gas Corporation (COG) shares were down in last trading by -3.75% to $21.79. It experienced higher than average volume on day. The stock decreased in value by almost -8.87% over the past week and grew 0.51% in the past month. It is currently trading -2.24% below its 50 day moving average and -8.09% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -18.43% decrease in value from its one year high of $26.74. The RSI indicator value of 42.77, lead us to believe that it is a hold for now.

Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale in northeast Pennsylvania with approximately 200,000 net acres in the dry gas window of the play; and the Eagle Ford Shale in south Texas with approximately 85,500 net acres in the oil window of the play. It also transports, stores, gathers, and purchases natural gas for resale. The company sells its natural gas to industrial customers, local distribution companies, and gas marketers through gathering systems and pipelines, as well as to intrastate pipelines, natural gas processors, and marketing companies. As of December 31, 2015, it had proved reserves of approximately 8,190 billion cubic feet of natural gas equivalent. The company was founded in 1989 and is headquartered in Houston, Texas.